Company says it has isolated virus strains for research
Shenzhen Kangtai Biological Products Co has successfully isolated multiple strains of the Delta variant of the coronavirus in a step that could lead to improved vaccines, media reported on Wednesday.
The report by Shenzhen Special Zone Daily quoted a company executive as saying quality requirements for human vaccines will be strictly followed in the evaluation of the isolated strains.
"In response to new challenges in global epidemic prevention and control, Kangtai will fully promote the R&D and industrialization of the vaccine against the coronavirus variant," the executive said, adding that the inactivated COVID-19 vaccine developed by the company and approved for emergency use in China, is still protective and produces a good immune response to a variety of coronavirus variants.
- How global readers understand Chinese modernization via new volume of 'Xi Jinping: The Governance of China'
- Investigation report on residential complex fire to be completed within 9 months: HKSAR chief executive
- Shaanxi court gives death penalty with reprieve to man who killed his wife
- More overseas talents return to China for entrepreneurship
- Yanshiping, Xizang's highest railway station, begins service
- Beijing reports childcare, elderly support progress during 14th Five-Year Plan period
